• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Patent holdings for IPC class C07D 231/12

Total number of patents in this class: 1980

10-year publication summary

163
144
146
131
144
109
122
111
83
90
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Principal owners for this class

Owner
All patents
This class
Bristol-myers Squibb Company
4824
48
Bayer Cropscience AG
1991
43
Takeda Pharmaceutical Company Limited
2716
41
Epizyme, Inc.
375
33
Arena Pharmaceuticals, Inc.
359
31
Novartis AG
10626
24
Boehringer Ingelheim International GmbH
4637
22
University of Southern California
2121
20
BASF SE
21072
19
Corteva Agriscience LLC
2705
19
Sumitomo Chemical Company, Limited
9110
17
F. Hoffmann-La Roche AG
7934
16
Janssen Pharmaceutica N.V.
3350
16
E. I. du Pont de Nemours and Company
3905
15
Bayer Pharma AG
1049
15
Bayer Animal Health GmbH
218
15
Merck Patent GmbH
5755
14
The Board of Trustees of the Leland Stanford Junior University
6526
14
FMC Corporation
830
14
Merck Sharp & Dohme LLC
3732
14
Other owners 1530